Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06060600 · ClinicalTrials.gov registry record
A Retrospective Analysis of Suramin Treatment for Stage 1 TBR
A clinical trial of Trypanosoma Brucei Rhodesiense; Infection, sponsored by Paxmedica.
- Completed
- Registry status
- 345
- Enrollment target
- 1
- Study location
NCT06060600: Completed study of Trypanosoma Brucei Rhodesiense; Infection, sponsored by Paxmedica.
NCT06060600 is a study of Trypanosoma Brucei Rhodesiense; Infection that has completed, run by Paxmedica. The registered enrollment target is 345 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06060600, a study of Trypanosoma Brucei Rhodesiense; Infection, has completed, sponsored by Paxmedica.
- COMPLETED
- Registry status
- 345 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will include TBR HAT patients treated with suramin between 2000 and 2020 at three sites in Uganda and Malawi A natural history cohort composed of source data from approximately 200 patients from a published epidemiological study will be used as a comparator. This study's objectives are to evaluate the efficacy and safety of suramin in the Stage 1 treatment of TBR HAT.
Primary Outcome
The primary efficacy analysis will compare the proportion alive and not meeting any of the following criteria * Death (both cohorts). * Progression from Stage 1 to Stage 2 TBR HAT as defined by meeting any of the following: * presence of TBR trypanosomes in the cerebrospinal fluid (CSF) * abnormal symptoms . * presence of TBR HAT symptoms for more than 2 months * Use of melarsoprol for clinical worsening or treatment failure * Moribund status
Conditions Studied
Study Locations (1)
New York
- PaxMedica - Tarrytown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2023-01-02 |
| Est. Completion | 2023-08-02 |
What the finished NCT06060600 record still lists
NCT06060600 is an observational study that tracks outcomes without assigning an intervention. The registered 345 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Trypanosoma Brucei Rhodesiense; Infection appearing as the primary indexed condition, and to 0 interventions.
NCT06060600 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06060600 about?
NCT06060600 is a clinical study titled "A Retrospective Analysis of Suramin Treatment for Stage 1 TBR". The study will include TBR HAT patients treated with suramin between 2000 and 2020 at three sites in Uganda and Malawi A natural history cohort composed of source data from approximately 200 patients from a published epidemiological study will be used as a comparator. This study's objectives are to...
What is the current status of trial NCT06060600?
This trial is currently completed. The enrollment target is 345 participants. The study started on 2023-01-02. Estimated completion is 2023-08-02.
What conditions does trial NCT06060600 study?
This clinical trial studies the following conditions: Trypanosoma Brucei Rhodesiense; Infection.
Who is sponsoring clinical trial NCT06060600?
This trial is sponsored by Paxmedica, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06060600 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- NCT05107674 · 345 participants · Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
- NCT05700279 · 345 participants · NA
Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset
- NCT05781100 · 345 participants · NA
Investigating Baby Behavior and Family Technology Use Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI